Allscripts Healthcare Solutions, Inc. (NASDAQ:MDRX) – Allscripts Expects Q4 Interim Sales Beat Consensus; Approves $250M Buyback

Allscripts Healthcare Solutions Inc (NASDAQ: MDRX) expects Q4 revenue of $390 million – $395 million, better than the consensus of $$386.75 million.

  • For FY21, the Company expects GAAP operating income of $70 million – $75 million and adjusted EBITDA of $295 million – $300 million, an increase from the prior outlook of $275 million – $285 million.
  • The Company also expects FY2021 cash flow from continuing operations of $245 million – $250 million.
  • It expects free cash flow to be between $165 million – $170 million, up from previous guidance of $145 million – $155 million.
  • Allscripts has announced a new share repurchase program to purchase up to $250 million shares. 
  • The new share repurchase program does not have a termination date and replaces the previous authorization to repurchase up to $350 million of common stock. 
  • In Q4 FY21, Allscripts repurchased $108 million shares.
  • Analyst Reaction: SVB Leerink analyst Stephanie Davis has upgraded Allscripts from Market Perform to Outperform and raised the price target from $19 to $22.
  • Price Action: MDRX shares are up 7.41% at $18.78 during the market session on the last check Tuesday.

Latest Ratings for MDRX

Date Firm Action From To
Jan 2022 SVB Leerink Upgrades Market Perform Outperform
Nov 2021 Deutsche Bank Maintains Hold
Aug 2021 RBC Capital Maintains Outperform

View More Analyst Ratings for MDRX

View the Latest Analyst Ratings

© 2022 Benzinga does not provide investment advice. All rights reserved.

Source link

Leave a Reply

Copyright © 2022 Billionaire Club Co LLC. All rights reserved

Loading the chat ...